Abstract: AIM: To evaluate the efficacy and adverse reactions of Gemicitabine / Lobaplatin (GL regimen) and Gemicitabine / Cisplatin ( GP regimen) in the treatment of metastatic breast cancer patients with anthracycline and taxane resistance.METHODS: A total of sixty-one patients with metastatic breast cancer were randomly assigned to receive the regimen of GL (n=30) or GP (n=31). GL regimen: Gemicitabine 1000 mg /m² by infusion on d1,d8,Lobaplatin 30 mg /m² on d1.GP regimen: Gemicitabine 1000 mg /m² by infusion on d1,d8,Cisplatin 25 mg /m² by infusion on d1-3.All the patients had failures and relapse after previous treatment with anthracycline and taxane.Twenty-one days was a cycle in the both two groups.Every patient was administered at least 2 cycles.RESULTS:The overall response rate(CR+PR) was 43.33% in GL regimen group and 38.71% in GP regimen group(P>0.05). The median time to progression (mTTP) in group GL and GP was 6.29 months and 5.59 months(P>0.05). There were more neutropenia and thrombocytopenia in the group GL, and more nausea and vomiting in the group GP. There were significant differences between the two groups(P<0.05).CONCLUSION: Both GL regimen and GP regimen are well effective for patients with anthracycline and taxane resistant metastatic breast cancer.And the response rate, median time to tumor progression were similar in both groups. The reaction of hematologic toxicity in the group GL was obviously higher than the group GP,but the gastrointestinal tract reaction was obviously higher in the group GP than the group GL. The two schemes may be suitable for different groups of people. And it is worthy of further clinical study.

Key words: Gemicitabine, Lobaplatin, Cisplatin, Metastatic breast cancer